Saxenda, a weight-loss medication, is expected to become available as a generic by 2031 [1].
When does the Saxenda patent expire?
The primary patent protecting Saxenda, with U.S. Patent No. 8,470,816, is set to expire in 2031 [1]. This patent covers the drug's active ingredient, liraglutide [2].
Can biosimilars be released before patent expiry?
While biosimilars for injectable drugs can sometimes enter the market before a primary patent expires, this often depends on the specific patent landscape and any ongoing legal challenges [3]. For Saxenda, the expiration of its key patent in 2031 is the current projected date for generic or biosimilar availability.
What does generic saxenda mean for patients?
The introduction of generic versions typically leads to lower prices for medications [3]. This could make Saxenda more accessible to patients seeking weight management treatment.
Who makes Saxenda?
Saxenda is manufactured by Novo Nordisk [4].
What is Saxenda used for?
Saxenda is a prescription medication used for chronic weight management in adults with obesity or who are overweight with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol [5]. It is indicated for use along with a reduced-calorie diet and increased physical activity [5].